Paul G Richardson

Paul G Richardson

UNVERIFIED PROFILE

Are you Paul G Richardson?   Register this Author

Register author
Paul G Richardson

Paul G Richardson

Publications by authors named "Paul G Richardson"

Are you Paul G Richardson?   Register this Author

100Publications

4283Reads

17Profile Views

Towards a better understanding of monoclonal gammopathy of renal significance.

Br J Haematol 2019 Sep 28;186(5):653-654. Epub 2019 May 28.

Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15989
Publisher Site
http://dx.doi.org/10.1111/bjh.15989DOI Listing
September 2019

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

N Engl J Med 2019 08;381(8):727-738

From the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai (A.C., S.P., S.J.), and New York University Langone Medical Center (D.K.) - both in New York; the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (D.T.V.); the School of Medicine, National and Kapodistrian University of Athens, Athens (M.G., M. Dimopoulos); the Winship Cancer Institute, Emory University, Atlanta (A.K.N., S.L.); Massachusetts General Hospital Cancer Center (A.J.Y.), Tufts Medical Center (R.L.C.), and the Dana-Farber Cancer Institute (P.G.R.), Boston, and Karyopharm Therapeutics, Newton (M.G.K., S.S., L.L., S. Tang, C.P., J.-R.S.-M., M.C., H.C., Y.L., J.S.) - all in Massachusetts; Johns Hopkins University, Baltimore (C.A.H.); the University of Nantes, Nantes (P.M.), Hôpital Necker (L.F.), Hôpital Saint-Antoine (M.M.), and La Pitié-Salpêtrière Hospital (S.C.), Paris, University Hospital, Lille (T.F.), Centre Hospitalier Lyon Sud, Pierre-Benite (L.K.), and Centre Hospitalo-Universitaire Vandoeuvre-lès-Nancy, Nancy (A.P.) - all in France; the Mayo Clinic, Rochester, MN (D.D.); the University of Michigan, Ann Arbor (C.C.); the Mayo Clinic of Arizona, Phoenix (A.K.S.); Hackensack University Medical Center, Hackensack, NJ (J.R.); Washington University School of Medicine, St. Louis (R.V.); Lineberger Comprehensive Cancer Center at University of North Carolina-Chapel Hill, Chapel Hill (S. Tuchman); the University of Heidelberg, Heidelberg (M.S.R.), University Medical Center Hamburg-Eppendorf, Hamburg (K.C.W.), the University of Tübingen, Tübingen (K.C.W.), University Hospital Würzburg, Würzburg (M.S.), the University of Freiburg, Freiburg (M.E.), and Gemeinschaftspraxis Hämatologie-Onkologie, Dresden (T.I.) - all in Germany; the University of Leuven, Leuven (M. Delforge), Institut Jules Bordet, Université Libre de Bruxelles, Brussels (N.M.), University Hospital Ghent, Ghent (P.V.), and Centre Hospitalier Universitaire Université Catholique de Louvain Namur, Yvoir (C.D.) - all in Belgium; Vanderbilt University Medical Center, Nashville (R.F.C.); Sylvester Cancer Center, University of Miami, Miami (J.E.H.); the University of Alabama at Birmingham, Birmingham (L.J.C.); Yale School of Medicine, New Haven, CT (T.L.P.); Baylor University Medical Center, Dallas (M.L.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (G.S.); and University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria (K.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1903455DOI Listing
August 2019

Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older.

J Geriatr Oncol 2019 May 22;10(3):486-489. Epub 2018 Nov 22.

Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Center for Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18794068183034
Publisher Site
http://dx.doi.org/10.1016/j.jgo.2018.10.010DOI Listing
May 2019

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 01 3;25(1):137-144. Epub 2018 Aug 3.

Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.07.039DOI Listing
January 2019

Ixazomib for the treatment of multiple myeloma.

Expert Opin Pharmacother 2018 Dec 13;19(17):1949-1968. Epub 2018 Nov 13.

g Hematology & Medical Oncology , Winship Cancer Institute, Emory University , Atlanta , GA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1528229DOI Listing
December 2018

The power of proteasome inhibition in multiple myeloma.

Expert Rev Proteomics 2018 12 14;15(12):1033-1052. Epub 2018 Nov 14.

b Medical Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14789450.2018.1543595DOI Listing
December 2018

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

N Engl J Med 2018 11;379(19):1811-1822

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Karol Marcinkowski University of Medical Sciences, Poznań (D.D.), and Silesian Medical University, Katowice (S.G.) - both in Poland; University Hospital, Nantes (P.M.), and Centre Hospitalier Universitaire de Poitiers-La Milétrie, Poitiers (X.L.) - both in France; National Hospital Organization Disaster Medical Center (N.T.) and the Japanese Red Cross Medical Center (K.S.), Tokyo, and Ibaraki Prefectural Central Hospital, Kasama (M.H.) - all in Japan; Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal (R.L.); Heidelberg University Hospital, Heidelberg, Germany (M.S.R.); Dana-Farber Cancer Institute, Boston (P.G.R.); Bristol-Myers Squibb, Princeton, NJ (M.P.M., Y.-M.J., S.G.S., M.R., B.R.); and Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain (J.S.-M.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805762
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805762DOI Listing
November 2018

An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.

Blood Adv 2018 10;2(19):2443-2451

Department of Medicine and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth and Dartmouth-Hitchcock Medical Center, Lebanon, NH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018016360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177641PMC
October 2018

How I treat the young patient with multiple myeloma.

Blood 2018 09 2;132(11):1114-1124. Epub 2018 Jul 2.

Dana Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Boston, MA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-05-693606DOI Listing
September 2018

Meaningful changes in end-of-life care among patients with myeloma.

Haematologica 2018 08 10;103(8):1380-1389. Epub 2018 May 10.

Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.187609DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068022PMC
August 2018

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

Br J Haematol 2018 08 29;182(4):495-503. Epub 2018 May 29.

Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105456PMC
August 2018

Maintenance and continuous therapy for multiple myeloma.

Expert Rev Anticancer Ther 2018 08 3;18(8):751-764. Epub 2018 Jul 3.

d Department of Haematology , Mater Misericordiae University Hospital, University College Dublin , Dublin , Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2018.1490181DOI Listing
August 2018

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.

Future Oncol 2018 May 22;14(11):1035-1047. Epub 2017 Dec 22.

Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215-5450, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0616DOI Listing
May 2018

Current use of monoclonal antibodies in the treatment of multiple myeloma.

Br J Haematol 2018 05 25;181(4):447-459. Epub 2018 Apr 25.

Dana Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15121DOI Listing
May 2018

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.

Br J Haematol 2018 05 10;181(4):433-446. Epub 2018 May 10.

Dana Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15116DOI Listing
May 2018

Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

Expert Rev Clin Pharmacol 2018 Feb 5;11(2):113-124. Epub 2018 Jan 5.

f Hematology Department , Hôpital Saint Antoine, AP-HP, Université Pierre & Marie Curie , Paris , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1421943DOI Listing
February 2018

Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.

Br J Haematol 2018 01 19;180(2):271-275. Epub 2017 Oct 19.

Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14970DOI Listing
January 2018

CD38 antibodies in multiple myeloma: back to the future.

Blood 2018 01 8;131(1):13-29. Epub 2017 Nov 8.

Laboratory of Immunogenetics, Department of Medical Sciences and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-06-740944DOI Listing
January 2018

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.

Expert Opin Pharmacother 2017 Dec 1;18(18):1975-1985. Epub 2017 Dec 1.

d Blood and Marrow Transplant Program , Roswell Park Cancer Institute , Buffalo , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2017.1409207DOI Listing
December 2017

The proteasome and proteasome inhibitors in multiple myeloma.

Cancer Metastasis Rev 2017 12;36(4):561-584

Dana-Farber Cancer Institute, 44 Binney Street, Dana 1B02, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-017-9707-8DOI Listing
December 2017

Optimizing therapy for del(17p) multiple myeloma.

Oncotarget 2017 Dec 6;8(66):109859-109860. Epub 2017 Dec 6.

University Cancer Center of Toulouse Institut National de la Santé, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746348PMC
December 2017

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure.

Int J Hematol Oncol 2017 Nov 11;6(3):75-93. Epub 2017 Aug 11.

Department of Pediatric Hematology, Oncology & Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/ijh-2017-0015
Publisher Site
http://dx.doi.org/10.2217/ijh-2017-0015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171967PMC
November 2017

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

J Clin Oncol 2017 Oct 25;35(29):3279-3289. Epub 2017 Jul 25.

Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.6679DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652871PMC
October 2017

Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.

Expert Rev Gastroenterol Hepatol 2017 Oct 4;11(10):885-898. Epub 2017 Sep 4.

b Harvard Medical School, Jerome Lipper Multiple Myeloma Center , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474124.2017.1
Publisher Site
http://dx.doi.org/10.1080/17474124.2017.1370372DOI Listing
October 2017

Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.

JAMA Oncol 2017 Jul;3(7):980-988

Cardiovascular Division, Vanderbilt University School of Medicine, Nashville, Tennessee2Cardio-Oncology Program,Vanderbilt University School of Medicine, Nashville, Tennessee3Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.3350DOI Listing
July 2017

Drug Combinations with Transplantation for Myeloma.

N Engl J Med 2017 07;377(1):93-94

Centre Hospitalier Universitaire de Nantes-Hôtel Dieu, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1705671DOI Listing
July 2017

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

N Engl J Med 2017 04;376(14):1311-1320

From the Institut Universitaire du Cancer de Toulouse-Oncopole (M.A., M.R., C.P., S.R., H.A.-L.) and Service d'Epidémiologie, Centre Hospitalier et Universitaire de Toulouse (V.L.-C.), Toulouse, Hôpital Haut-Lévêque, Bordeaux Pessac (C.H.), Centre Hospitalier et Universitaire la Miletrie, Poitiers (X.L.), Centre Hospitalier Le Bocage, Dijon (D.C.), Centre Hospitalier et Universitaire de Rennes, Rennes (M.E.), Hôpital St.-Louis (B.A., J.P.F.), Centre Hospitalier Universitaire, Hôpital St.-Antoine (L.G.), Institut Curie (C.M.), and Haute Autorité de Santé (J.-L.H.), Paris, Institut d'Hématologie de Basse Normandie, Centre Hospitalier et Universitaire de Caen, Caen (M.M.), Centre Hospitalier et Universitaire Henri Mondor, Creteil (K.B.), Hôpital Claude Huriez, Lille (T.F.), and Hôtel Dieu, Nantes (P.M.) - all in France; Institut Jules Bordet, Brussels (N. Meuleman); and Dana-Farber Cancer Institute, Boston (M.E.M., A.A.Z., E.A.W., N. Munshi, K.C.A., P.G.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611750DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201242PMC
April 2017

Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma.

Pharmacol Res 2017 03 21;117:185-191. Epub 2016 Nov 21.

Clínica Universidad de Navarra, Universidad de Navarra, CIMA, IDISNA, Av. de Pio XII, 36, 31008 Pamplona, Navarra, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2016.11.020DOI Listing
March 2017

Deacetylase inhibitors: an advance in myeloma therapy?

Expert Rev Hematol 2017 Mar 1;10(3):229-237. Epub 2017 Feb 1.

a Department of Hematologic Malignancies , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1280388DOI Listing
March 2017

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 10;375(14):1319-1331

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona (A.O.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); Tom Baker Cancer Centre, University of Calgary, Calgary, AB (N.J.B.), and the Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto (D.R.) - both in Canada; Levine Cancer Institute-Carolinas HealthCare System, Charlotte, NC (S.Z.U.); the Department of Haematology, University College London Hospitals NHS Trust, London (N.R.); the Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); the Department of Hematology and Stem Cell Transplantation, Poznan University of Medical Sciences, Poznan, Poland (M.K.); the Department of Hematology, Japanese Red Cross Medical Center, Tokyo (K.S.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.), and Genmab, Copenhagen (S.L.) - both in Denmark; the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); the Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem (D.B.Y.); Dana-Farber Cancer Institute, Harvard Medical School, Boston (P.G.R.); University Hospital Heidelberg and the German Cancer Research Center, Heidelberg, Germany (H.G.); Janssen Research and Development, Spring House, PA (N.Z.K., L.O., C.C., X.Q., M.G., T.A.); and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France (P.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1607751DOI Listing
October 2016

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

Clin Cancer Res 2016 Aug 22;22(16):4206-4214. Epub 2016 Mar 22.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987182PMC
August 2016

A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.

Br J Haematol 2016 08 20;174(3):397-409. Epub 2016 Apr 20.

Department of Medical Oncology, The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961600PMC
August 2016

Point/Counterpoint: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma. One Size does not fit all.

Oncology (Williston Park) 2016 08;30(8):747-9

View Article

Download full-text PDF

Source
August 2016

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.

J Clin Oncol 2016 05 14;34(13):1544-57. Epub 2016 Mar 14.

Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0044DOI Listing
May 2016

Dual inhibition of oncogenic targets for B-cell malignancies.

Lancet Oncol 2016 05 31;17(5):547-9. Epub 2016 Mar 31.

Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)00109-1DOI Listing
May 2016

Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma.

Br J Haematol 2016 Apr 20;173(1):82-8. Epub 2016 Jan 20.

Department of Haematology, Mater Misericordiae University Hospital, Dublin 7, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13928DOI Listing
April 2016

The Future of Myeloma Therapy: One Size Does Not Fit All.

J Oncol Pract 2016 Apr;12(4):295-6

Dana-Farber Cancer Institute, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.011502DOI Listing
April 2016

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 Apr;374(17):1621-34

From University Hospital Hôtel Dieu, Nantes (P.M., C.T.), the Department of Hematology, Institut Paoli-Calmettes, Marseille (A.-M.S.), and the Department of Hematology and Cell Therapy, Hospital Saint Antoine, Paris (L.G.) - all in France; the Department of Haematology and Stem Cell Transplantation, St. István and St. László Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary (T.M.); the Department of Haemato-oncology and Bone Marrow Transplantation, Medical University of Lublin, and St. John's Cancer Center, Lublin, Poland (N.G.); Southern Alberta Cancer Research Institute, University of Calgary, Calgary (N.J.B.), and the Division of Hematology, Department of Medicine, University of Alberta, Edmonton (I.S.) - both in Canada; the Department of Hematology, Skåne University Hospital, Lund University, Lund, Sweden (M.H.); Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (L.P.); the Department of Haematology, Christchurch Hospital, Christchurch (P. Ganly), the Department of Haematology, Palmerston North Hospital, Palmerston North, Manawatu (B.W.B.), the Department of Haematology, Middlemore Hospital, Auckland (S.R.J.), and the Department of Haematology, North Shore Hospital, Auckland (D.R.S.) - all in New Zealand; the Department of Hematology, University Hospital Rigshospitalet, Copenhagen (P. Gimsing); Myeloma Unit, Division of Hematology, University of Turin, Turin (A.P.), and Seràgnoli Institute of Haematology, Bologna University School of Medicine, St. Orsola-Malpighi University Hospital, Bologna (M.C.) - both in Italy; the Division of Hematology, Mayo Clinic, Rochester, MN (S.K., F.K.B.); and Dana-Farber Cancer Institute, Boston (J.P.L., P.G.R.), and Millennium Pharmaceuticals, Cambridge (D.T.B., J.L., A.D.B., A.-M.H., H.V.) - both in Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1516282DOI Listing
April 2016

Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series.

Clin Lymphoma Myeloma Leuk 2016 Mar 2;16(3):e39-45. Epub 2015 Dec 2.

Department and Clinic of Haematology, Jagiellonian University Medical College, Krakow, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.11.020DOI Listing
March 2016